Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RGL-2102
- Development stage
- Phase 3
- Lead developer
- Regenelead Therapies
- Administration
- Topical, Intramuscular
01
Overview
RGL-2102 is an investigational drug developed by Shanghai Regenelead Therapies for the treatment of chronic wounds and severe lower limb ischemia. It is being evaluated in both topical and injectable formulations, with clinical trials focusing on its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy. The exact mechanism of action has not been disclosed publicly. Clinical development includes Phase 1 and Phase 2 studies in China for chronic wounds (topical administration) and severe lower limb ischemia (intramuscular injection)[1][2][3].
Beyond the preview
Go deeper on RGL-2102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RGL-2102.